ASHAP - An effective salvage therapy for recurrent and refractory malignant lymphomas

Annals of Hematology

Volumn 79, Issue 6, 2000, Pages 304-311

  Hanel M ^b   Kroger N ^a   Hoffknecht, M M ^a   Peters, S O ^a   Metzner, B ^c   Fiedler, F ^b   Braumann, D ^d   Schubert, J C ^e   Illiger, H J ^c   Hanel A ^b   Kruger W H ^a   Zeller, W ^a   Weh, H J ^a   Hossfeld, D K ^a   Zander, A R ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Department of Hematology   (Germany)

^c Department of Oncology/Hematology   (Germany)

^d ASKLEPIOS KLINIK ALTONA   (Germany)

^e StJoseph Hospital Bremerhaven   (Germany)

Author keywords

ASHAP protocol; Autologous stem cell transplantation; High dose therapy; Hodgkin's disease; Non Hodgkin's lymphoma; Salvage therapy

Indexed keywords

CISPLATIN; CYTARABINE; DOXORUBICIN; LACTATE DEHYDROGENASE; METHYLPREDNISOLONE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; FEMALE; GASTROINTESTINAL SYMPTOM; HODGKIN DISEASE; HUMAN; INFECTION; LEUKOPENIA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NEPHROTOXICITY; NEUROTOXICITY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; REMISSION; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CYTARABINE; DOXORUBICIN; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; METHYLPREDNISOLONE HEMISUCCINATE; MIDDLE AGED; RECURRENCE; SALVAGE THERAPY; SURVIVAL ANALYSIS;

EID: 0343963313     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002779900150     Document Type: Article

References (54)

1. Longo DL, Duffey PL, Young RC, Hubbard SM, Ihde DC, Glatstein E, Phares JC, Jaffe ES, Urba WJ, De Vita VT, Jr (1992) Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure. J Clin Oncol 10 : 210-218
2. Gisselbrecht C, Bosly A, Lepage E, Reyes F, Philip T, Haioun C, Tilly H, Coiffier B (1993) Autologous hematopoietic stem cell transplantation in intermediate and high grade non-Hodgkin's lymphoma: a review. Ann Oncol 4[suppl 1] : 7-13
3. Cabanillas F, Hagemeister FB, Bodey GP, Freireich EJ (1982) IMVP-16: an effective regimen for patients with lymphoma who have relapsed after initial chemotherapy. Blood 60 : 693-697
4. Cabanillas F, Hagemeister FB, McLaughlin P, Velasquez WS, Riggs S, Fuller L, Smith T (1987) Results of MIME salvage regimen for recurrent or refractory lymphoma. J Clin Oncol 5 : 407-412
5. Rodriguez MA, Cabanillas F, Hagemeister FB, Mc Laughlin P, Romaguera JE, Swan F, Velasquez WS (1995) A phase II trial of mesna / ifosfamide, mitoxantrone and etoposide for refractory lymphomas. Ann Oncol 6 : 609-611
6. Santoro A, Viviani S, Bonfante V, Valagussa P, Bonadonna C (1987) CEP in Hodgkin's disease (HD) resistant to MOPP and ABVD (abstract). Proc Am Soc Clin Oncol 6 : 199
7. Pfreundschuh MG, Schoppe WD, Fuchs R, Pflüger KH, Löffler M, Diehl V (1987) Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and darcabazine (ABVD): a multicenter trial of the German Hodgkin's Study Group. Cancer Treat Rep 71 : 1203-1207
8. Chopra R, Linch DC, McMillan AK, Blair S, Patterson KG, Moir D, Richards JDM, Cervi P, Kinsey S, Goldstone AH (1992) Mini-BEAM followed by BEAM and ABMT for very poor risk Hodgkin's disease. Br J Haematol 81 : 197-202
9. Pfreundschuh MG, Rueffer U, Lathan B, Schmitz N, Brosteanu O, Hasenclever D, Haas R, Kirchner H, Koch P, Kuse R, Loeffler M, Diehl V (1994) Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimes: a trial of the German Hodgkin's Disease Study Group. J Clin Oncol 12 : 580-586
10. Philip T, Armitage JO, Spitzer G, Chauvin F, Jagannath S, Cahn JY, Colombat P, Goldstone AH, Gorin NC, Flesh M, Laporte JP, Maraninchi D, Pico J, Bosly A, Anderson C, Schots R, Biron P, Cabanillas F, Dicke K (1987) High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med 316 : 1493-1498
11. Cabanillas F, Velasquez WS, McLaughlin P, Jagannath S, Hagemeister FB, Redman JR, Swan F, Rodriguez MA (1988) Results of recent salvage chemotherapy regimes for lymphoma and Hodgkin's disease. Semin Hematol 25[suppl 2] : 47-50
12. Appelbaum FR, Thomas ED (1989) Review of the use of marrow transplantation in the treatment of non-Hodgkin's lymphomas. J Clin Oncol 7 : 440-447
13. Armitage JO (1992) Autologous bone marrow transplantation for Hodgkin's disease. Ann Oncol 3[suppl 4] : 95-96
14. Rossof AH, Coltman Jr CA, Jones SE, Talley RW (1979) Phase II evaluation of cis-dichlorodiammineplatinum(II) in lymphomas: a Southwest Oncology Group Study. Cancer Treat Rep 63 : 1605-1608
15. Cavalli F, Jungi WF, Nissen NI, Pajak TF, Coleman M, Holland JF (1981) Phase II trial of cis-dichlorodiammineplatinum(II) in advanced malignant lymphoma: a study of the cancer and acute leukemia group B. Cancer 48 : 1927-1930
16. Bergerat JP, Drewinko B, Corry P, Barlogie B, Ho HD (1981) Synergistic lethal effect of cis-dichlorodiammine-platinum and 1-βb-D-arabinofuranosylcytosine. Cancer Res 41 : 25-30
17. Comella P, Abate G, Di Finizio G, Daponte A, Zarrilli D (1990) Treatment of resistant non-Hodgkin's-lymphoma with cisplatin, etoposide, and bleomycin. Cancer Chemother Pharmacol 26 : 306-309
18. Velasquez WS, Cabanillas F, Salvador P, Mc Laughlin P, Fridrik M, Tucker S, Jagannath S, Hagemeister FB, Redman JR, Swan F, Barlogie B (1988) Effective salvage therapy for lymphoma with cisplatin in combination high-dose Ara-C and dexamethasone (DHAP). Blood 71 : 117-122
19. Velasquez WS, McLaughlin P, Tucker S, Hagemeister FB, Swan F, Rodriguez MA, Romaguera J, Rubenstein E, Cabanillas F (1994) ESHAP-an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 12 : 1169-1176
20. Brandwein JM, Callum J, Sutcliffe SB, Scott JG, Keating A (1990) Evaluation of cytoreductive therapy prior to high dose treatment with autologous bone marrow transplantation in relapsed and refractory Hodgkin's disease. Bone Marrow Transplant 5 : 99-103
21. Press OW, Livingston R, Mortimer J, Collins C, Appelbaum F (1991) Treatment of relapsed non-Hodgkin's lymphoma with dexamethasone, high-dose cytarabine, and cisplatin before marrow transplantation. J Clin Oncol 9 : 423-431
22. Zinzani PL, Martelli M, Tura S, Mandelli F (1993) Granulocyte colony stimulating factor (G-CSF) as adjunct therapy in relapsed-resistant high-grade non-Hodgkin's lymphoma. Haematologica 78 : 40-43
23. Ezzat AA, Khalifa F, Berry J, Khan B, Raja MA, Abdel-Warith A (1994) ESHAP: an effective treatment in selected patients with relapsed non-Hodgkin's lymphoma. Ann Oncol 5 : 453-546
24. Velasquez WS, Dunphy F, Santillana S, Adkins D, Bowers C, Broun Jr GO, Petruska PJ, Spitzer G (1993) ASHAP, an effective treatment for relapsing and refractory Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL) (abstract). Blood 82[suppl 1] : 138a
25. Peters SO, Schmitz N, Metzner H, Illiger HJ, Schubert JC, Weh HJ, Hossfeld DK, Zander AR (1993) Adriamycin, cisplatin, ara-c and methylprednisolone (ASHAP) combination chemotherapy in relapsed and refractory lymphoma and Hodgkin's disease - preliminary data (abstract). Blood 82[suppl 1] : 574a
26. Velasquez W, Dunphy F, Petruska P, Adkins D, Broun G, Jr, Spitzer G (1995) ASHAP with or without ABMT for high risk non-Hodgkin's lymphoma (NHL) (abstract). Proc ASCO 14 : 387
27. Lennert K, Mohri N, Stein H, Kaiserling E (1975) The histopathology of malignant lymphoma. Br J Haematol 31[suppl] : 193-203
28. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assess 53 : 457
29. Peto R, Peto J (1972) Asymptotically efficient rank invariation test procedures (with discussion). J R Stat Soc A 135 : 185
30. Liepman MK, Wheeler RH, Zuckerman KS, Lobuglio AF (1982) Combination chemotherapy of refractory lymphoma with cis-dichlorodiammineplatinum, vinblastine, and bleomycin. Cancer 50 : 2736-2739
31. Corder MP, Clamon GH (1984) Salvage therapy of aggressive non-Hodgkin's lymphoma with a combination of vinblastine, bleomycin, and cisplatin. Cancer 54 : 202-206
32. Judson IR, Wiltshaw E (1985) Cis-dichlorodiammineplatinum (cis-platinum) and etoposide (VP-16) in malignant lymphoma - an effective salvage regimen. Cancer Chemother Pharmacol 14 : 258-261
33. Tubiana N, Lejeune C, Horchowski N, Gastaut JA, Finaud M, Sainty D, Sebahoun G, Carcassonne Y (1987) Etoposide and cisplatinum in resistant lymphomas. Cancer Chemother Pharmacol 20 : 179-180
34. Rodriguez-Monge EJ, Cabanillas F (1997) Long-term follow-up of platinum based lymphoma salvage regimens. The M.D. Anderson Cancer Center Experience. Hematol Oncol North Am 11 : 937-947
35. Lai GM, Chen YN, Mickley LA, Fojo AT, Bates SE (1991) P-glycoprotein expression and schedule dependence of adriamycin cytotoxicity in human colon carcinoma cell lines. Int J Cancer 49 : 669-673
36. Zhan Z, Kang YK, Regis J, Shives B, Bryant G, Wilson W, Fojo AT, Bates S (1993) Taxol resistance: in vitro and in vivo studies in breast cancer and lymphoma (abstract). Proc Am Assoc Cancer Res 34 : 215
37. Wilson WH, Bryant G, Bates S, Fojo A, Wittes RE, Steinberg SM, Kohler DR, Jaffe ES, Herdt J, Cheson BD, Chabner BA (1993) EPOCH Chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. J Clin Oncol 11 : 1573-1582
38. Rodriguez MA, Cabanillas FC, Velasquez WS, Hagemeister FB. McLaughlin P, Swan F, Romaguera JE (1995) Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP. J Clin Oncol 13: 1734-1741
39. Rodriguez J, Rodriguez MA, Fayad L, Hagemeister B, McLaughlin P, Swan F, Sarris A, Romaguera J, Andersson B, Cabanillas F (1998) ASHAP is an effective salvage regimen in patients with refractory or recurrent Hodgkin's disease. Blood 93 : 3632-3636
40. Desch CE, Lasala MR, Smith TJ, Hillner BE (1992) The optimal timing of autologous bone marrow transplantation in Hodgkin's disease patients after a chemotherapy relapse. J Clin Oncol 10 : 200-209
41. Bosly A, Coiffier B, Gisselbrecht C, Tilly H, Auzanneau G, Andrien F, Herbrecht R, Legros M, Devaux Y, Jaubert J, et al. (1992) Bone marrow transplantation prolongs survival after relapse in aggressive-lymphoma patients treated with the LNH-84 regimen. J Clin Oncol 10 : 1615-1623
42. Linch DC, Winfield D, Goldstone AH, et al. (1993) Dose intensification with autologous bone marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 341 : 1051-1054
43. Coiffier B, Bosly A, Tilly H, sebban C, Herbrecht R, Gisselbrecht C (1994) Long-term outcome of aggressive lymphoma patients treated with the LNH-84 protocol: relapsing patients may be salvaged by intensive therapy with stem cell transplantation (ITwSCT) (abstract). Proc ASCO 13 : 372
44. Meehan KR, Pritchard RS, Leichter JW, Littenberg B, Welch HG (1995) Autologous bone marrow transplantation versus chemotherapy in relapsed/refractory non-Hodgkin's lymphoma: estimates of long-term survival from the recent literature. Am J Hematol 50 : 116-123
45. Philip T, Guglielmi C, Hagenbeek A, Somers R, van der Lelie H, Bron D, Sonneveld P, Gisselbrecht C, Cahn JY, Harousseau JL, Coiffier B, Biron P, Mandelli F, Chauvin F (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333 : 1540-1545
46. Fielding AK, Pearce RM, Taghipour G, et al. (1997) Autologous transplantation for lymphoma - trends over 15 years from 3750 cases reported to the EBMT lymphoma registry. What have we learned? In: Schmitz N (ed) Rezidivtherapie hochmaligner Non-Hodgkin-Lymphome. Internist 38 : 143-149
47. Armitage JO (1993) Treatment of non-Hodgkin's lymphoma. N Engl J Med 328 : 1023-1030
48. Schmitz N, Sextro M, Hasenclever D, Carella A, Fiedler F, Schlimok G, Hossfeld DK, Diehl V (1997) HD-R1: first results of a randomized trial comparing aggressive chemotherapy with high-dose therapy (HDT) and hematopoietic stem cell transplantation (HSCT) in patients with chemosensitive relapse of Hodgkin's disease (HD) (abstract). Blood 90[suppl 1] : 115a
49. Vose JM, Anderson JR, Kessinger A, Bierman PJ, Coccia P, Reed EC, Gordon P, Armitage JO (1993) High-dose chemotherapy and autologous hematopoietic stem cell transplantation for aggressive non-Hodgkin's lymphoma. J Clin Oncol 11 : 1846-1851
50. Wheeler C, Strawderman M, Ayash L, Churchill WH, Bierer BE, Elias A, Gilliland DG, Antman K, Guinan EC, Eder JP, Weinstein H, Schwartz G, Ferrara J, Mazanet R, Rimm IJ, Tepler I, McCarthy P, Mauch P, Ault K, Gaynes L, McCauley M, Schnipper LE, Antin J (1993) Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine, and etoposide. J Clin Oncol 11 : 1085-1091
51. Rapoport AP, Rowe JM, Kouides PA, Duerst RA, Abboud CN, Liesveld JL, Packman CH, Ebely S, Sherman M, Tanner MA, Constine LS, DiPersio JF (1993) One hundred autotransplants for relapsed or refractory Hodgkin's disease and lymphoma: value of pretransplant disease status for predicting outcome. J Clin Oncol 11 : 2351-2361
52. Mahendra P, Johnson D, Hood IM, Scott MA, Barker P, Bass G, Jestice HK, Bloxham DM, Boraks P, Wimperis JZ, Baglin TP, Marcus RE (1996) High-dose therapy and autologous stem cell rescue for poor risk and refractory lymphoma: a single centre experience of 123 patients. Bone Marrow Transplant 17 : 973-978
53. Prince HM, Imrie K, Crump M, Stewart AK, Girouard C, Colwill R, Brandwein J, Tsang RW, Scott JG, Sutton DM, Pantalony G, Carstairs K, Sutcliffe SB, Keating A (1996) The role of intensive therapy and autologous blood and marrow transplantation for chemotherapy-sensitive relapsed and primary refractory non-Hodgkin's lymphoma: identification of major prognostic groups. Br J Haematol 4 : 880-889
54. Rapoport AP, Lifton R, Constine LS, Duerst RE, Abbound CN, Liesveld JL, Packman CH, Eberly S, Raubertas RF, Martin BA, Flesher WR, Kouides PA, DiPersio JF, Rowe JM (1997) Autotransplantation for relapsed or refractory non-Hodgkin's lymphoma (NHL): long-term follow-up and analysis of prognostic factor. Bone Marrow Transplant 19 : 883-890